Expression of GOLPH2 is associated with the progression of and poor prognosis in gastric cancer

Liu,Guanglin; Zhang,Yan; He,Fen; Li,Jianfeng; Wei,Xuan; Li,Yang; Liao,Xiaowen; Sun,Jiancong; Yi,Wei; Niu,Daoli

doi:10.3892/or.2014.3404

Expression of GOLPH2 is associated with the progression of and poor prognosis in gastric cancer

Authors:
- Guanglin Liu
- Yan Zhang
- Fen He
- Jianfeng Li
- Xuan Wei
- Yang Li
- Xiaowen Liao
- Jiancong Sun
- Wei Yi
- Daoli Niu
View Affiliations

Affiliations: Department of Radiation Oncology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P.R. China, Department of Medical Oncology, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, P.R. China
Published online on: August 14, 2014 https://doi.org/10.3892/or.2014.3404
Pages: 2077-2085

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Golgi phosphoprotein 2 (GOLPH2) has been associated with the development and progression of various human cancers. The aims of this study were to investigate the relationship between GOLPH2 and gastric cancer (GC) progression and explore the clinical significance of GOLPH2 in GC. GOLPH2 expression was examined in four pairs of primary GC tissues and the adjacent non-cancerous tissues from the same patients, using immunohistochemistry (IHC), quantitative PCR and western blotting. Furthermore, GOLPH2 protein expression was analyzed in 10 normal gastric tissues and 385 clinicopathologically characterized cases of GC by IHC. Statistical analyses were performed to determine the prognostic and diagnostic associations. GOLPH2 mRNA and protein expression were both markedly upregulated in GC tissues, compared with the paired adjacent non-cancerous tissues. The Chi-square test and Spearman analysis revealed a significant correlation between GOLPH2 expression and clinical stage, T classification, lymph node metastasis, metastasis and venous invasion. Patients with a higher GOLPH2 expression had a shorter overall survival (OS), compared to patients with lower GOLPH2 expression. Notably, our results suggested that GOLPH2 is associated with the development and progression of GC. Therefore, additional studies focusing on the potential of GOLPH2 as a novel therapeutic target in GC are required.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Roder DM: The epidemiology of gastric cancer. Gastric Cancer. 5(Suppl 1): 5–11. 2002. View Article : Google Scholar
3	Paoletti X, Oba K, Burzykowski T, et al: Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 303:1729–1737. 2010. View Article : Google Scholar : PubMed/NCBI
4	Liu JH, Song LB, Zhang X, et al: Bmi-1 expression predicts prognosis for patients with gastric carcinoma. J Surg Oncol. 97:267–272. 2008. View Article : Google Scholar : PubMed/NCBI
5	Gou HF, Chen XC, Zhu J, et al: Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications. J Exp Clin Cancer Res. 30:142011. View Article : Google Scholar : PubMed/NCBI
6	Aoki M, Ishigami S, Uenosono Y, et al: Expression of BMP-7 in human gastric cancer and its clinical significance. Br J Cancer. 104:714–718. 2011. View Article : Google Scholar : PubMed/NCBI
7	Zhou F, Li N, Jiang W, et al: Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial. World J Surg Oncol. 10:2742012. View Article : Google Scholar : PubMed/NCBI
8	Li W, Yu CP, Xia JT, et al: Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res. 15:1393–1399. 2009. View Article : Google Scholar : PubMed/NCBI
9	Kladney RD, Bulla GA, Guo L, et al: GP73, a novel Golgi-localized protein upregulated by viral infection. Gene. 249:53–65. 2000. View Article : Google Scholar : PubMed/NCBI
10	Mao Y, Yang H, Xu H, et al: Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut. 59:1687–1693. 2010. View Article : Google Scholar : PubMed/NCBI
11	Kristiansen G, Fritzsche FR, Wassermann K, et al: GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer. 99:939–948. 2008. View Article : Google Scholar : PubMed/NCBI
12	Fritzsche FR, Riener MO, Dietel M, Moch H, Jung K and Kristiansen G: GOLPH2 expression in renal cell cancer. BMC Urol. 8:152008. View Article : Google Scholar : PubMed/NCBI
13	Fritzsche FR, Kristiansen G, Riener MO, Dietel M and Oelrich B: GOLPH2 expression may serve as diagnostic marker in seminomas. BMC Urol. 10:42010. View Article : Google Scholar : PubMed/NCBI
14	Zhang F, Gu Y, Li X, Wang W, He J and Peng T: Up-regulated Golgi phosphoprotein 2 (GOLPH2) expression in lung adenocarcinoma tissue. Clin Biochem. 43:983–991. 2010. View Article : Google Scholar : PubMed/NCBI
15	Marrero JA, Romano PR, Nikolaeva O, et al: GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 43:1007–1012. 2005. View Article : Google Scholar : PubMed/NCBI
16	Riener MO, Stenner F, Liewen H, et al: Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology. 49:1602–1609. 2009. View Article : Google Scholar : PubMed/NCBI
17	Kladney RD, Cui X, Bulla GA, Brunt EM and Fimmel CJ: Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology. 35:1431–1440. 2002. View Article : Google Scholar : PubMed/NCBI
18	Hu JS, Wu DW, Liang S and Miao XY: GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med Oncol. 27:339–345. 2010. View Article : Google Scholar : PubMed/NCBI
19	Wang M, Long RE, Comunale MA, et al: Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 18:1914–1921. 2009. View Article : Google Scholar : PubMed/NCBI
20	Liu X, Wan X, Li Z, Lin C, Zhan Y and Lu X: Golgi protein 73(GP73), a useful serum marker in liver diseases. Clin Chem Lab Med. 49:1311–1316. 2011.PubMed/NCBI
21	Iftikhar R, Kladney RD, Havlioglu N, et al: Disease- and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol. 99:1087–1095. 2004. View Article : Google Scholar : PubMed/NCBI
22	Hann HW, Wang M, Hafner J, et al: Analysis of GP73 in patients with HCC as a function of anti-cancer treatment. Cancer Biomark. 7:269–273. 2010.PubMed/NCBI
23	Ozkan H, Erdal H, Tutkak H, et al: Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma. Digestion. 83:83–88. 2011. View Article : Google Scholar : PubMed/NCBI
24	Laxman B, Morris DS, Yu J, et al: A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 68:645–649. 2008. View Article : Google Scholar : PubMed/NCBI